Proprotein Convertase Subtilisin-Kexin Type 9 inhibitors and stroke prevention: A meta-analysis
Publication date
2021-03
Authors
Sagris, Dimitrios
Ntaios, George
Georgiopoulos, Georgios
Pateras, Konstantinos
Milionis, Haralampos
Editors
Advisors
Supervisors
Document Type
Comment
Metadata
Show full item recordCollections
License
taverne
Abstract
Keywords
Alirocumab, Evolocumab, Lipid-lowering, PCSK9 inhibitor, Statin, Stroke, Taverne, Internal Medicine
Citation
Sagris, D, Ntaios, G, Georgiopoulos, G, Pateras, K & Milionis, H 2021, 'Proprotein Convertase Subtilisin-Kexin Type 9 inhibitors and stroke prevention : A meta-analysis', European journal of internal medicine, vol. 85, no. 3, pp. 130-132. https://doi.org/10.1016/j.ejim.2020.11.021